New MainStream Adds On to Platform Companies

New MainStream Adds On to Platform Companies

The recent crop of healthcare services platforms owned by New MainStream Capital is moving to the add-on stage. Last week brought two acquisition announcements from Omni Eye Services and CORDENTAL Group. Both companies were acquired in 2017. New MainStream committed $25 million in equity capital to buy CORDENTAL in March 2017. The Cincinnati-based company is a dental support organization that provides business support services to affiliated dental practices in the Mid-Atlanta, Midwestern and Southeastern regions. Omni Eye Services, based in Iselin, New Jersey, is an optometric referral practice providing a full range of specialty services for the advanced treatment of eye diseases. No... Read More »
Deal of the Week: UnitedHealth Buys Banmedica SA

Deal of the Week: UnitedHealth Buys Banmedica SA

UnitedHealth Group (NYSE: UNH) wasted no time dwelling on its recent acquisition of DaVita Medical Group (NYSE: DVA) for $4.9 billion. On December 22, the healthcare giant announced its acquisition of Chilean healthcare company Banmedica SA (SSE: SGO) for $2.8 billion. Banmeica sells health insurance, operates hospitals and provides other services. It generated approximately $2.1 billion in revenue last year and has operations in Chile, Columbia and Peru. UnitedHealth is looking to grow in emerging and established global healthcare markets where it can leverage its expertise as both an insurer and a provider of medical care. The transaction enables Banmedica to leverage United... Read More »

Deal of the Week: CVS/Aetna

The biggest deal of the year (so far) was announced on Sunday, December 3, no doubt timed to give media outlets a fresh story to begin the week. By now you know that CVS Health Corp. (NYSE: CVS) and managed care giant Aetna (NYSE: AET) plan to merge in mid-2018, to the tune of $77 billion (including Aetna’s debt). The deal was first reported in October by The Wall Street Journal, with talk of $200 to $205 per share for Aetna. The final price is $207 per share in cash and stock: $145 in cash and $62 in stock. Besides being the largest deal announced in 2017 (since 2015, in fact), the unusual combination portends major changes in the U.S. healthcare market. Or not. Skeptics abound regarding... Read More »
Stat of the Week: ‘Other Services’ Drops 19% in Q3:17

Stat of the Week: ‘Other Services’ Drops 19% in Q3:17

Investors have flocked to the “Other Services” sector this year, as its ancillary nature keeps the companies that comprise it largely outside the purview of reimbursement regulations and other stroke-of-the-pen sectors. The 42 transactions announced in this sector in the third quarter represent a 19% decrease from the previous quarter, and a 32% decrease compared with the year-earlier quarter.  Deal volume accounted for 22% of the 192 deals announced in the past 12 months. The “Other Services” category covers products and services related to human health care, but in an ancillary way, such as contract research organizations, ambulatory surgery centers, institutional and... Read More »
Cardinal Health Sheds its China Operations

Cardinal Health Sheds its China Operations

Cardinal Health Inc. (NYSE: CAH) put its Cardinal Health China business up for sale in July of this year, following concerns that upcoming drug distribution reform could threaten the company’s growth. Cardinal’s China business is the eighth largest drug distributor in the country, operating 14 direct sales units and 17 distribution centers that cover 322 cities and 11,000 medical institutions. The bidding process was very competitive, according to Reuters, and names like Warburg Pincus were rumored to have competed in the final rounds, among other private equity and Chinese pharmaceutical bidders. On November 14th, Cardinal Health announced that Shanghai Pharmaceuticals Holding Co., Ltd.... Read More »
Deal of the Week: McKesson/RxCrossroads

Deal of the Week: McKesson/RxCrossroads

The largest deal announced in a very sluggish week for healthcare announcements was McKesson Corp.’s (NYSE: MCK) $735 million acquisition of RxCrossroads from CVS Health Corp. (NYSE: CVS). RxCrossroads provides a range of specialty distribution, pharmacy and patient support to biopharmaceutical manufacturers. CVS acquired it in 2015 as part of its $12.7 billion deal for Omnicare Inc., which specialized in managing pharmaceutical care in long-term care and assisted living facilities. Omnicare paid $235 million for RxCrossroads in 2005, when it reported annualized revenue of $46 million. For McKesson, RxCrossroads will help it to capitalize on what the coming boom in the specialty... Read More »